Rehaler receives 19 million DKK from EU to advance innovative migraine treatment towards the market
EU’s EIC Accelerator program has awarded the Danish medtech company Rehaler 11 mDKK (1.48 mEUR) in grant and a further 8 mDKK (1.08 mEUR) in equity investment, supporting its groundbreaking migraine treatment device. The funding will empower Rehaler to greatly expand its recently launched pivotal clinical trial, as well as to commence market preparation and expansion of its team.
”This grant and equity investment represent a huge milestone for us as a company and for our technology, and serves as a clear validation of our value proposition for patients, clinicians and society at large”, said Rehaler’s CEO Troels Johansen.
“This is the first migraine treatment of its kind so it is absolutely crucial to conduct gold-standard, large-scale clinical validation. The EIC has now made that possible by allowing us to add a number of additional trial sites in USA and Europe, expanding the size of the trial from 60 patients to 220. The funding also provides crucial support for market preparation, production upscaling, regulatory activities, and expansion of our team”.
Rehaler’s migraine treatment device is a small drug-free inhaler that works by accurately controlling the inspired levels of CO2 and oxygen.
”It has been known since 1950 that CO2/oxygen mixtures inhibit migraine attacks but this is the first device that is able to deliver the correct mixture in a way which is both safe and practical in use”, said Troels Johansen.
The 10 gram device is developed from a prototype which demonstrated proof of concept in a pilot study at Aarhus University Hospital (Denmark). The results were published in Cephalalgia which is the highest ranked scientific headache journal in the world.
Rehaler’s first commercial target is migraine with aura which has a prevalence in the population of 4%.
”Three out of four migraine patients are not satisfied with their current treatment, which shows a significant need for new effective treatments”, added Troels Johansen.
Rehaler was one of only 51 companies who received EIC Accelerator funding, out of a total of 551 pre-selected applicants.
Kontakter
Troels JohansenCEO, Rehaler
Tlf:+45 40 97 73 13tj@rehaler.comBilleder
About Rehaler
Rehaler is a private medical technology company developing and commercializing novel treatments based on modulation of CO2 and oxygen in the central nervous system. Rehaler has obtained proof-of-concept for its first product, a pocket sized device for treatment of migraine with aura. Rehaler recently initiated its pivotal clinical registration study which will pave the way for FDA approval, commercial launch and market adoption. The company’s technology platform has applications in several other neurological disorders which will be investigated alongside the registration study. Read more at www.rehaler.com.
Følg pressemeddelelser fra Rehaler A/S
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Rehaler A/S
Rehaler modtager bevilling på 2.18 mio. kr. fra Innovationsfonden til ny migræne-behandling6.4.2022 10:50:00 CEST | Pressemeddelelse
Innovationsfonden har tildelt Rehaler en Innobooster- bevilling på 2.18 mio. kr. til det kliniske forsøg som skal dokumentere effekten af den danske medtech-virksomheds device til behandling af migræne. Forsøget gennemføres i samarbejde med hovedpinecentre i USA, Tyskland, Italien og Storbritannien. Et positivt resultat vil åbne for FDA-godkendelse og global kommercialisering af Rehaler-produktet
Rehaler closes financing round and strengthens Board of Directors1.12.2021 11:30:00 CET | Press release
Financing round of 6.1 MDKK Proceeds will be used to prepare for a clinical registration study in patients with migraine with aura Four new members with significant experience from the medical technology industry elected to the Board of Directors Rehaler, a private medical technology company focusing on an innovative treatment solution for migraine with aura, today announced the successful closing of a finance round totaling 6.1 MDKK and the appointment of Mette Gross, Martin Møller, Helene Quie and Martin Waleij to its Board of Directors. “We are very pleased with having received the confidence of several knowledgeable and experienced Scandinavian private investors. This financing will be used to mature the company and prepare for a pivotal clinical registration study for our novel device which represents a new treatment option for patients with migraine with aura. The objective is to obtain registration in the U.S. and create data supporting the commercialization of the device in bot